-
August 24, 2017
Aileron Therapeutics Announces Presentation of Preclinical Data with ALRN-6924 at the International Society of Experimental Hematology Annual Scientific Meeting
-
August 10, 2017
Aileron Therapeutics Reports Second Quarter 2017 Financial Results
-
August 3, 2017
Aileron Therapeutics to Present at Canaccord Genuity 37th Annual Growth Conference
-
June 28, 2017
Aileron Therapeutics Announces Pricing of Initial Public Offering
-
June 15, 2017
Aileron Therapeutics Appoints Donald Dougherty as Senior Vice President and Chief Financial Officer
-
June 3, 2017
Anti-tumor Activity Observed in Phase 1 Trial of Novel P53-Targeting Drug ALRN-6924
-
May 18, 2017
Aileron Therapeutics Announces Oral Presentation at ASCO on ALRN-6924 Targeting p53